DE60233558D1 - Aminosäurezusammensetzungen zur linderung einer fehlfunktion der leber - Google Patents
Aminosäurezusammensetzungen zur linderung einer fehlfunktion der leberInfo
- Publication number
- DE60233558D1 DE60233558D1 DE60233558T DE60233558T DE60233558D1 DE 60233558 D1 DE60233558 D1 DE 60233558D1 DE 60233558 T DE60233558 T DE 60233558T DE 60233558 T DE60233558 T DE 60233558T DE 60233558 D1 DE60233558 D1 DE 60233558D1
- Authority
- DE
- Germany
- Prior art keywords
- amino acid
- liver
- low
- functional disorders
- level
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 150000001413 amino acids Chemical class 0.000 title abstract 7
- 210000004185 liver Anatomy 0.000 title abstract 6
- 239000000203 mixture Substances 0.000 title abstract 6
- 229940024606 amino acid Drugs 0.000 abstract 6
- 235000001014 amino acid Nutrition 0.000 abstract 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 4
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 abstract 2
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 abstract 2
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 abstract 2
- 239000006035 Tryptophane Substances 0.000 abstract 2
- 239000008280 blood Substances 0.000 abstract 2
- 210000004369 blood Anatomy 0.000 abstract 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 abstract 2
- 229960004799 tryptophan Drugs 0.000 abstract 2
- 235000017103 tryptophane Nutrition 0.000 abstract 2
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 abstract 1
- 239000004475 Arginine Substances 0.000 abstract 1
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 abstract 1
- 239000004471 Glycine Substances 0.000 abstract 1
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 abstract 1
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 abstract 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 abstract 1
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 abstract 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 abstract 1
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 abstract 1
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 abstract 1
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 abstract 1
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 abstract 1
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 abstract 1
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 abstract 1
- AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 abstract 1
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 abstract 1
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 abstract 1
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 abstract 1
- 239000004472 Lysine Substances 0.000 abstract 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 abstract 1
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 abstract 1
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 abstract 1
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 abstract 1
- 239000004473 Threonine Substances 0.000 abstract 1
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 abstract 1
- 231100000570 acute poisoning Toxicity 0.000 abstract 1
- 235000004279 alanine Nutrition 0.000 abstract 1
- 229960003767 alanine Drugs 0.000 abstract 1
- 235000009697 arginine Nutrition 0.000 abstract 1
- 229960003121 arginine Drugs 0.000 abstract 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 abstract 1
- 235000003704 aspartic acid Nutrition 0.000 abstract 1
- 229960005261 aspartic acid Drugs 0.000 abstract 1
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 235000013922 glutamic acid Nutrition 0.000 abstract 1
- 229960002989 glutamic acid Drugs 0.000 abstract 1
- 239000004220 glutamic acid Substances 0.000 abstract 1
- 229960002449 glycine Drugs 0.000 abstract 1
- 235000014304 histidine Nutrition 0.000 abstract 1
- 229960002885 histidine Drugs 0.000 abstract 1
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 abstract 1
- 235000014705 isoleucine Nutrition 0.000 abstract 1
- 229960000310 isoleucine Drugs 0.000 abstract 1
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 abstract 1
- 235000005772 leucine Nutrition 0.000 abstract 1
- 229960003136 leucine Drugs 0.000 abstract 1
- 235000018977 lysine Nutrition 0.000 abstract 1
- 229960003646 lysine Drugs 0.000 abstract 1
- 235000006109 methionine Nutrition 0.000 abstract 1
- 229930182817 methionine Natural products 0.000 abstract 1
- 229960004452 methionine Drugs 0.000 abstract 1
- 235000008729 phenylalanine Nutrition 0.000 abstract 1
- 229960005190 phenylalanine Drugs 0.000 abstract 1
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 abstract 1
- 229960002429 proline Drugs 0.000 abstract 1
- 235000004400 serine Nutrition 0.000 abstract 1
- 229960001153 serine Drugs 0.000 abstract 1
- 229960002898 threonine Drugs 0.000 abstract 1
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 abstract 1
- 235000002374 tyrosine Nutrition 0.000 abstract 1
- 229960004441 tyrosine Drugs 0.000 abstract 1
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 abstract 1
- 235000014393 valine Nutrition 0.000 abstract 1
- 229960004295 valine Drugs 0.000 abstract 1
- 239000004474 valine Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/401—Proline; Derivatives thereof, e.g. captopril
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
- A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
- A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4172—Imidazole-alkanecarboxylic acids, e.g. histidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
Landscapes
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Addiction (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Psychiatry (AREA)
- Neurosurgery (AREA)
- Gastroenterology & Hepatology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Meat, Egg Or Seafood Products (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2001074964 | 2001-03-15 | ||
| PCT/JP2002/002500 WO2002074302A1 (fr) | 2001-03-15 | 2002-03-15 | Compositions d'acides amines utilisees pour ameliorer l'insuffisance hepatique |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DE60233558D1 true DE60233558D1 (de) | 2009-10-15 |
Family
ID=18932127
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DE60233558T Expired - Fee Related DE60233558D1 (de) | 2001-03-15 | 2002-03-15 | Aminosäurezusammensetzungen zur linderung einer fehlfunktion der leber |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US20040192751A1 (de) |
| EP (1) | EP1374863B1 (de) |
| JP (1) | JPWO2002074302A1 (de) |
| AT (1) | ATE441409T1 (de) |
| DE (1) | DE60233558D1 (de) |
| TW (1) | TWI309162B (de) |
| WO (1) | WO2002074302A1 (de) |
Families Citing this family (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102512408B (zh) | 2004-11-26 | 2015-11-25 | Ucl商业有限公司 | 用于治疗肝性脑病的含有鸟氨酸和苯基乙酸或苯基丁酸的组合物 |
| WO2007023931A1 (ja) * | 2005-08-25 | 2007-03-01 | Kyowa Hakko Kogyo Co., Ltd. | 血中アルコール濃度上昇抑制用組成物 |
| EP2413924B1 (de) | 2009-04-03 | 2017-09-27 | Ocera Therapeutics, Inc. | L-ornithin-phenyl-acetat und verfahren zu seiner herstellung |
| CN102625699B (zh) | 2009-06-08 | 2014-08-20 | Ucl商业有限公司 | 使用l-鸟氨酸苯乙酸盐治疗门静脉高压和恢复肝功能 |
| KR101213825B1 (ko) * | 2010-07-16 | 2012-12-18 | 서울대학교산학협력단 | 세린을 유효성분으로 함유하는 지방간 질환의 예방 및 치료용 조성물 |
| EP2625162B1 (de) | 2010-10-06 | 2019-03-13 | Ocera Therapeutics, Inc. | Verfahren zur herstellung von l-ornithin-phenyl-acetat |
| CN113633777A (zh) | 2014-11-24 | 2021-11-12 | Ucl商业有限公司 | 使用降氨疗法治疗与肝星状细胞激活相关的疾病 |
| JP2016132622A (ja) * | 2015-01-16 | 2016-07-25 | イーエヌ大塚製薬株式会社 | 敗血症治療又は予防用栄養組成物 |
| CA2995823A1 (en) | 2015-08-18 | 2017-02-23 | Ocera Therapeutics, Inc. | Treatment and prevention of muscle loss using l-ornithine in combination with at least one of phenylacetate and phenylbutyrate |
| JOP20190146A1 (ar) | 2016-12-19 | 2019-06-18 | Axcella Health Inc | تركيبات حمض أميني وطرق لمعالجة أمراض الكبد |
| US11224582B2 (en) | 2017-04-25 | 2022-01-18 | Almeda Labs Llc | Amino acid formulations for pancreatic viability |
| JP7126520B2 (ja) | 2017-05-11 | 2022-08-26 | オセラ セラピューティクス， インコーポレイテッド | Ｌ－オルニチンフェニルアセテートを製造する方法 |
| WO2019036471A1 (en) * | 2017-08-14 | 2019-02-21 | Axcella Health Inc. | AMINO ACIDS BRANCHED FOR THE TREATMENT OF LIVER DISEASE |
| SG11202001327RA (en) * | 2017-08-30 | 2020-03-30 | Asahi Group Holdings Ltd | Composition for reducing serum uric acid level |
| JP2021066662A (ja) * | 2018-02-15 | 2021-04-30 | 国立大学法人東北大学 | 肝脂肪低減剤 |
| WO2019246221A1 (en) * | 2018-06-20 | 2019-12-26 | Axcella Health Inc. | Compositions and methods for the treatment of liver diseases and disorders |
| AR115585A1 (es) | 2018-06-20 | 2021-02-03 | Axcella Health Inc | Composiciones y métodos para el tratamiento de la infiltración de grasa en músculo |
| CN111329836B (zh) * | 2020-04-08 | 2021-04-30 | 河北科星药业有限公司 | 畜用复方氨基酸注射液的制备方法 |
| CN111265476B (zh) * | 2020-04-08 | 2021-05-04 | 河北科星药业有限公司 | 一种畜用复方氨基酸注射液的制备方法 |
| CN111358753A (zh) * | 2020-04-08 | 2020-07-03 | 河北科星药业有限公司 | 畜用复方氨基酸注射液及其制备方法 |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3950529A (en) * | 1975-02-03 | 1976-04-13 | Massachusetts General Hospital | Amino acid formulations for patients with liver disease and method of using same |
| JPS568312A (en) * | 1979-07-03 | 1981-01-28 | Otsuka Pharmaceut Factory Inc | Amino acid pharmaceutical preparation |
| JPS6354320A (ja) * | 1986-08-26 | 1988-03-08 | Ajinomoto Co Inc | 抗アルコ−ル症組成物 |
| JP2518692B2 (ja) * | 1989-06-14 | 1996-07-24 | 理化学研究所 | 筋力持続剤，滋養強壮剤，輸液用剤，栄養補給剤，疲労回復剤及び乳酸生成調節剤 |
| US5266685A (en) * | 1992-05-05 | 1993-11-30 | Grain Processing Corporation | Non-bitter protein hydrolyzates |
| JPH0624976A (ja) * | 1992-07-10 | 1994-02-01 | Rikagaku Kenkyusho | 輸液用組成物 |
| US5981472A (en) * | 1997-02-21 | 1999-11-09 | Dx/Ibr Corporation | Methods for treating diseases |
| JPH11302164A (ja) * | 1998-04-20 | 1999-11-02 | Shimizu Pharmaceutical Co Ltd | アミノ酸組成物 |
| US6506552B2 (en) * | 1998-08-24 | 2003-01-14 | Meiji Dairies Corporation | Amino acid-trehalose composition |
| JP2000072669A (ja) * | 1998-08-24 | 2000-03-07 | Inst Of Physical & Chemical Res | アミノ酸・糖組成物 |
-
2002
- 2002-03-15 AT AT02705258T patent/ATE441409T1/de not_active IP Right Cessation
- 2002-03-15 US US10/471,850 patent/US20040192751A1/en not_active Abandoned
- 2002-03-15 TW TW091104902A patent/TWI309162B/zh not_active IP Right Cessation
- 2002-03-15 DE DE60233558T patent/DE60233558D1/de not_active Expired - Fee Related
- 2002-03-15 WO PCT/JP2002/002500 patent/WO2002074302A1/ja active Application Filing
- 2002-03-15 JP JP2002573010A patent/JPWO2002074302A1/ja active Pending
- 2002-03-15 EP EP02705258A patent/EP1374863B1/de not_active Expired - Lifetime
Also Published As
| Publication number | Publication date |
|---|---|
| US20040192751A1 (en) | 2004-09-30 |
| JPWO2002074302A1 (ja) | 2005-07-14 |
| ATE441409T1 (de) | 2009-09-15 |
| EP1374863B1 (de) | 2009-09-02 |
| WO2002074302A1 (fr) | 2002-09-26 |
| EP1374863A4 (de) | 2005-01-12 |
| EP1374863A1 (de) | 2004-01-02 |
| TWI309162B (en) | 2009-05-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE60233558D1 (de) | Aminosäurezusammensetzungen zur linderung einer fehlfunktion der leber | |
| AR051512A1 (es) | Proteina de fusion que comprende un dominio bh3 de una proteina "solo bh3" | |
| DE602006018856D1 (de) | Neue nutrazeutika-zusammensetzungen | |
| BR9812634A (pt) | April - uma proteìna com efeitos de crescimento | |
| DK1706457T3 (da) | Fremstilling af 3-hydroxypropionsyre ved anvendelse af beta-alanin/pyruvataminotransferase | |
| ES2113606T3 (es) | Cetonas peptidicas como inhibidores de la enzima convertidora de la interleuquina-1beta. | |
| BR0313970A (pt) | Composições pesticidas contendo ácidos dicarboxìlicos | |
| EA200800233A1 (ru) | Композиция иммуноконьюгата | |
| BRPI0112584B8 (pt) | ésteres oxigenados de derivados de ácido benzidroxâmico de 4-iodofenilamino, composição farmacêutica e combinação | |
| DE69723812D1 (de) | Aminosäurezusammensetzungen | |
| TW200509899A (en) | Amino acid composition and supplemental solution | |
| EA200802128A1 (ru) | Новые нутрицевтические композиции | |
| WO2005034932A3 (en) | Amino acid based compositions for the treatment of pathological conditions distinguished by insufficient mitochondrial function | |
| BR0109846A (pt) | Uso de uma composição que compreende um anticorpo ou um fragmento de ligação de antìgeno deste, e conjunto | |
| EP1908492A4 (de) | Metabotroper glutamat-rezeptor-aktivator | |
| DE60129137D1 (de) | Modulierung durch il-tif/interleukin-21 | |
| MA30139B1 (fr) | Preparation de gamma-aminoacides ayant une affinite pour la proteine alpha-2-delta. | |
| KR970005043B1 (en) | Tumor necrosis factor alpha muteins | |
| ATE418877T1 (de) | Essbare bzw. trinkbare sowie medizinisch verwendbare, die körpertemperatur erhöhende aminosäurezusammensetzung | |
| DE60118935D1 (de) | Dna & protein bindende miniatur proteine | |
| ATE446360T1 (de) | Mittel zur senkung der blutviskosität | |
| EA200501230A1 (ru) | Жидкие составы фактор некроза опухоли - связывающих белков | |
| DK1204679T3 (da) | Peptider som indeholder N-substituerede D-aminosyrer til at forhindre associering af Beta-strenge | |
| BR9711540A (pt) | Inibidores de protease proteìnico estabilizados e variantes dos mesmos | |
| MXPA03001304A (es) | Acidos amino(oxo)aceticos inhibidores de la proteina tirosina fosfatasa. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| 8364 | No opposition during term of opposition | ||
| 8339 | Ceased/non-payment of the annual fee |